retatrutide and autoimmune disease Frontiers Weight loss with retatrutide as

Reported side effects in studies include: nausea diarrhea constipation vomiting abdominal discomfort These effects were generally dose-dependent and more common during the early stages of treatment

What happens next in this space Retatrutides Phase 3 program (called TRIUMPH) includes multiple ongoing trials across different patient populations, with additional results expected throughout 2026

The trials could lead to new and more effective ways to address the obesity epidemic by shedding light on the possible advantages and disadvantages of this weight-management therapy option

The separation between metabolic health and mental health has always been more administrative than biological